Varda Space Industries

Overview

Develops and operates reusable in-space manufacturing capsules that leverage microgravity to produce materials impossible or difficult to make on Earth — initially pharmaceuticals (ritonavir crystals demonstrated on W-Series 1, 2024). Capsules launched on SpaceX rideshare and return via terrestrial reentry after manufacturing missions.

Moat: First company to complete an end-to-end commercial in-space manufacturing mission (W-Series 1, 2024 — ritonavir crystal growth + reentry). Proprietary reentry capsule and manufacturing platform. Pharmacy-grade GMP in-space manufacturing is a regulatory moat; very few peers at this stage.

Business

Primary customers

• Commercial: Pharmaceutical / biotech companies
• Government: U.S. Government (potential defense and materials R&D)

Sectors

In-space manufacturing · Pharmaceuticals · Reentry capsules

Key Products

• W-Series Capsuleoperational

  Reusable in-space manufacturing and reentry capsule. W-Series 1 completed a 47-day mission in 2024 growing ritonavir pharmaceutical crystals.

  First flight: 2023-06-12

Recent Milestones

1. 2024

   W-Series 1 completes 47-day mission — first commercial in-space pharmaceutical manufacturing, ritonavir crystals grown and successfully recovered via reentry capsule

   [1]
2. 2025-07

   Series C $187M raise (~$329M total funding); continues W-Series mission development

   [2]

What investors should know

Sources & References